Strategies for Improving Linkage-to-Care After Eye Disease Screening
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Apr 17, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to find better ways to help people get the eye care they need after being screened for eye diseases like Age-Related Macular Degeneration, Diabetic Retinopathy, and Glaucoma. If you've participated in the Village Integrated Eye Worker II (VIEW II) study and were referred to an eye hospital after your screening, you might be eligible for this trial. Participants will be randomly assigned to one of three groups: one will receive text message reminders, another will have reminders from community health workers, and the last group will not receive any reminders. The main goal is to see if these different methods help encourage people to visit the eye hospital within 21 days of their screening.
The trial is not yet recruiting participants, and it is open to everyone aged 18 and older, as long as they live in an area with reliable mobile connectivity. If you join the trial, you can expect to either receive reminders to help you remember your appointment or not have any reminders at all, which will help the researchers understand the best ways to support people in getting the eye care they need. This trial is important because it aims to improve follow-up care for people with serious eye conditions, ultimately helping to protect their vision.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Participant of the VIEW II study referred to the eye hospital at their eye screening visit.
- Exclusion Criteria:
- • Residence in a community without reliable mobile connectivity
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Patients applied
Trial Officials
Jeremy Keenan, MD, MPH
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported